hDHODH-IN-7
DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a human dihydroorotate dehydrogenase inhibitor. DHODH-IN-9 has antiviral effect with a pMIC50 of 7.4.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1644156-41-1
- 화학식: C21H23FN4O
- 분자량:366.43
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-108325
BrequinarDHODH Inhibitor -
HY-128787
hDHODH-IN-4DHODH Inhibitor -
HY-135570
hDHODH-IN-3HsDHODH Inhibitor -
HY-14908
VidofludimusDHODH Inhibitor -
HY-112645
BAY-2402234DHODH Inhibitor -
HY-108325R
Brequinar (Standard)DHODH Inhibitor -
HY-129239
FarudodstatDHODH Inhibitor -
HY-101813
LaflunimusImmunomodulator/DHODH Inhibitor -
HY-100688
ML390DHODH Inhibitor -
HY-139189
JNJ-74856665DHODH Inhibitor -
HY-100184
DSM265DHODH Inhibitor -
HY-137463
AG-636DHODH Inhibitor
All DNA/RNA Synthesis Isoforms
More
Biological Activity
제품 설명
IC50 & Target
pMIC50: 7.4 (DHODH)[1]
In Vitro
DHODH-IN-9 (Compound 10k) is a corresponding pyridazine homologue from 3-chloro-6-cyclopropylpyridazine. With few variations, the pattern of antiviral effect for analogues featuring a 5-cyclopylpyridine is somehow mirroring the one seen for the 5-ethylpyrimidyl bearing homologues. DHODH-IN-9 (Compound 10k) is a good antiviral of this group of analogue[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1644156-41-1
-
분자량 366.43
-
화학식 C21H23FN4O
-
SMILES
CC(C)OC1=NN(C2=NC=C(C3CC3)C=N2)C(C)=C1CC4=CC=CC=C4F
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
hDHODH-IN-7 Related Classifications
HY-135667 Related Classifications
Powered by Bioz